286 related articles for article (PubMed ID: 27627986)
1. Interest in Integrative Medicine Among Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study.
Hack CC; Fasching PA; Fehm T; de Waal J; Rezai M; Baier B; Baake G; Kolberg HC; Guggenberger M; Warm M; Harbeck N; Wuerstlein R; Deuker JU; Dall P; Richter B; Wachsmann G; Brucker C; Siebers JW; Fersis N; Kuhn T; Wolf C; Vollert HW; Breitbach GP; Janni W; Landthaler R; Kohls A; Rezek D; Noesslet T; Fischer G; Henschen S; Praetz T; Heyl V; Kühn T; Krauss T; Thomssen C; Hohn A; Tesch H; Mundhenke C; Hein A; Rauh C; Bayer CM; Jacob A; Schmidt K; Belleville E; Hadji P; Brucker SY; Wallwiener D; Kümmel S; Beckmann MW; Paepke D
Integr Cancer Ther; 2017 Jun; 16(2):165-175. PubMed ID: 27627986
[TBL] [Abstract][Full Text] [Related]
2. Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.
Dunn C; Keam SJ
Pharmacoeconomics; 2006; 24(5):495-517. PubMed ID: 16706574
[TBL] [Abstract][Full Text] [Related]
3. A prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving patients' persistence to adjuvant aromatase inhibitor medication for postmenopausal, early stage breast cancer.
Yu KD; Zhou Y; Liu GY; Li B; He PQ; Zhang HW; Lou LH; Wang XJ; Wang S; Tang JH; Liu YH; Wang X; Jiang ZF; Ma LW; Gu L; Cao MZ; Zhang QY; Wang SM; Su FX; Zheng H; Li HY; Tang LL; Sun SR; Liu JP; Shao ZM; Shen ZZ
Breast Cancer Res Treat; 2012 Jul; 134(1):307-13. PubMed ID: 22527106
[TBL] [Abstract][Full Text] [Related]
4. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
[TBL] [Abstract][Full Text] [Related]
5. Letrozole : in postmenopausal hormone-responsive early-stage breast cancer.
Scott LJ; Keam SJ
Drugs; 2006; 66(3):353-62. PubMed ID: 16526826
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer in Korea.
Beom SH; Oh J; Kim TY; Lee KH; Yang Y; Suh KJ; Moon HG; Han SW; Oh DY; Han W; Kim TY; Noh DY; Im SA
Cancer Res Treat; 2017 Apr; 49(2):454-463. PubMed ID: 27554482
[TBL] [Abstract][Full Text] [Related]
7. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
8. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
[TBL] [Abstract][Full Text] [Related]
9. Letrozole in postmenopausal hormone-responsive early-stage breast cancer : a viewpoint by Laura B. Michaud.
Michaud LB
Drugs; 2006; 66(3):363-4. PubMed ID: 16526827
[No Abstract] [Full Text] [Related]
10. Letrozole in postmenopausal hormone-responsive early-stage breast cancer: a viewpoint by Gerald M. Higa.
Higa GM
Drugs; 2006; 66(3):363-4. PubMed ID: 16526828
[No Abstract] [Full Text] [Related]
11. [Introduction of new drug: letrozole, a new non-steroidal aromatase inhibitor for the treatment of postmenopausal women with breast cancer].
Tsukagoshi S
Gan To Kagaku Ryoho; 2006 Jun; 33(6):859-63. PubMed ID: 16770112
[TBL] [Abstract][Full Text] [Related]
12. An overview of letrozole in postmenopausal women with hormone-responsive breast cancer.
Barnadas A; Estévez LG; Lluch-Hernández A; Rodriguez-Lescure A; Rodriguez-Sanchez C; Sanchez-Rovira P
Adv Ther; 2011 Dec; 28(12):1045-58. PubMed ID: 22068628
[TBL] [Abstract][Full Text] [Related]
13. Letrozole: advancing hormone therapy in breast cancer.
Lee RJ; Armstrong AC; Wardley AM
Womens Health (Lond); 2012 Nov; 8(6):611-8. PubMed ID: 23181527
[TBL] [Abstract][Full Text] [Related]
14. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Goss PE; Ingle JN; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Tu D; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Therasse P; Palmer MJ; Pater JL
N Engl J Med; 2003 Nov; 349(19):1793-802. PubMed ID: 14551341
[TBL] [Abstract][Full Text] [Related]
15. Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer.
Mouridsen HT; Robert NJ
MedGenMed; 2005 Aug; 7(3):20. PubMed ID: 16369246
[TBL] [Abstract][Full Text] [Related]
16. Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial.
Llombart-Cussac A; Ruiz A; Antón A; Barnadas A; Antolín S; Alés-Martínez JE; Alvarez I; Andrés R; García Saenz JA; Lao J; Carrasco E; Cámara C; Casas I; Martín M
Cancer; 2012 Jan; 118(1):241-7. PubMed ID: 21717449
[TBL] [Abstract][Full Text] [Related]
17. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate.
Buzdar A; Douma J; Davidson N; Elledge R; Morgan M; Smith R; Porter L; Nabholtz J; Xiang X; Brady C
J Clin Oncol; 2001 Jul; 19(14):3357-66. PubMed ID: 11454883
[TBL] [Abstract][Full Text] [Related]
18. The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: a prospective, randomized, phase II trial.
Safra T; Bernstein-Molho R; Greenberg J; Pelles-Avraham S; Stephansky I; Sarid D; Inbar MJ; Stemmer SM; Geffen DB
Oncology; 2011; 81(5-6):298-305. PubMed ID: 22156381
[TBL] [Abstract][Full Text] [Related]
19. Incidence and Predictive Factors for Recovery of Ovarian Function in Amenorrheic Women in Their 40s Treated With Letrozole.
Krekow LK; Hellerstedt BA; Collea RP; Papish S; Diggikar SM; Resta R; Vukelja SJ; Holmes FA; Reddy PK; Asmar L; Wang Y; Fox PS; Peck SR; O'Shaughnessy J
J Clin Oncol; 2016 May; 34(14):1594-600. PubMed ID: 26884554
[TBL] [Abstract][Full Text] [Related]
20. Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study.
Wallwiener M; Nabieva N; Feisst M; Fehm T; de Waal J; Rezai M; Baier B; Baake G; Kolberg HC; Guggenberger M; Warm M; Harbeck N; Wuerstlein R; Deuker JU; Dall P; Richter B; Wachsmann G; Brucker C; Siebers JW; Popovic M; Kuhn T; Wolf C; Vollert HW; Breitbach GP; Janni W; Landthaler R; Kohls A; Rezek D; Noesselt T; Fischer G; Henschen S; Praetz T; Heyl V; Kühn T; Krauss T; Thomssen C; Hohn A; Tesch H; Mundhenke C; Hein A; Rauh C; Bayer CM; Schmidt K; Belleville E; Brucker SY; Hadji P; Beckmann MW; Wallwiener D; Kümmel S; Hartkopf A; Fasching PA
BMC Cancer; 2019 Jun; 19(1):611. PubMed ID: 31227025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
